Tesamorelin vs GHRP-6

Tesamorelin and GHRP-6 are both research peptides studied across multiple applications, yet they operate through fundamentally different pathways. Tesamorelin, a synthetic analog of growth hormone-releasing hormone (GHRH), directly stimulates pituitary GH secretion in a pulsatile manner, mimicking physiological regulation. In contrast, GHRP-6 is a ghrelin receptor agonist that acts as a growth hormone secretagogue, amplifying endogenous GH pulses while also triggering distinct non-endocrine effects. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps, particularly in studies involving body composition, metabolism, and tissue protection.

It stimulates endogenous GH and IGF-1 production. Phase 3 trials demonstrated significant visceral fat reduction with a generally well-tolerated safety profile over 26 weeks of therapy.By binding to GHRH receptors on pituitary somatotrophs, it stimulates endogenous GH and IGF-1 production in a manner that preserves the natural pulsatile secretion pattern. A notable recent development is Egrifta WR, a weekly-reconstitution formulation approved by the FDA in March 2025, which offers improved dosing convenience. Phase 3 trials demonstrated significant visceral adipose tissue reduction over 26 weeks, with a generally well-tolerated safety profile. Research indicates tesamorelin also increases skeletal muscle area and density, and remains effective in patients on integrase strand transfer inhibitor (INSTI)-based HIV regimens, which are associated with weight gain.

GHRP-6 (Growth Hormone-Releasing Peptide 6) is a synthetic hexapeptide that functions as a potent growth hormone secretagogue by binding to the ghrelin receptor (GHS-R1a). It stimulates pulsatile GH release from the pituitary while maintaining physiological feedback controls. It is one of the earliest GH-releasing peptides developed and is notable for strong appetite stimulation via ghrelin receptor activation. Beyond endocrine effects, GHRP-6 exhibits cytoprotective properties through the CD36 receptor, with preclinical data showing cardioprotective, neuroprotective, and anti-fibrotic effects.Unlike tesamorelin, it amplifies endogenous GH pulsatility while maintaining physiological feedback controls, including sensitivity to somatostatin. As one of the earliest GH-releasing peptides developed, GHRP-6 is notable for its strong appetite-stimulating effects via ghrelin receptor activation, which can confound body composition studies. Beyond endocrine actions, preclinical research has revealed cytoprotective properties mediated through the CD36 receptor, with studies showing cardioprotective effects in models of ischemia-reperfusion injury, neuroprotection in experimental stroke, and anti-fibrotic activity in hepatic and cardiac tissues. These non-endocrine effects distinguish GHRP-6 from other GH secretagogues and broaden its research potential.

Both peptides are studied for their effects on body composition, though through distinct mechanisms. Tesamorelin's primary research application is in reducing visceral adipose tissue and improving metabolic parameters, particularly in HIV-associated lipodystrophy. GHRP-6 is also investigated for body composition, but its strong appetite stimulation can complicate interpretation of weight-related outcomes. Tesamorelin has no additional unique applications beyond its endocrine effects, while GHRP-6 is additionally explored for cytoprotective and tissue-protective effects in preclinical models, including cardiac ischemia, stroke, and fibrosis. Researchers should consider these differences when designing studies, as GHRP-6's pleiotropic effects may introduce confounding variables not present with tesamorelin.

Tesamorelin: Common adverse effects in clinical trials include injection site reactions (17%), arthralgia (13%), myalgia (6%), and peripheral edema (6%). Headache, nausea, and flu-like symptoms are also reported. Tesamorelin may increase blood glucose levels, so glucose monitoring is recommended in diabetic subjects. Long-term safety data from phase 3 trials support a generally well-tolerated profile over 26 weeks. GHRP-6: The most notable side effect is intense hunger due to ghrelin receptor activation, which is more pronounced than with other GH secretagogues and can impact study outcomes. Transient mild increases in cortisol and ACTH have been observed but are typically not clinically significant. Water retention and bloating are also reported. Researchers should monitor for these effects, particularly in studies where appetite or fluid balance could confound results.